Key facts
- This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Feb 2025, 16:22.
Eric Easom - 26 Feb 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANTX
- Reported as of
- 26 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2025, 16:22:36 UTC
- Prior SEC filing
- 18 Nov 2024
- Next SEC filing
- 03 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 28 Feb 2025.
Change
- Previous filing in this sequence was filed on 18 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +145,250
- Change %
- +144%
- Price
- $0.000000
- Shares after
- 246,380
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ANTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,065,766
- Date
- 26 Feb 2025
- Ownership
- See Footnote
- Footnotes
- F3
ANTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 97,058
- Date
- 26 Feb 2025
- Ownership
- See Footnote
- Footnotes
- F4
ANTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 97,058
- Date
- 26 Feb 2025
- Ownership
- See Footnote
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +290,500
- Change %
- Price
- $0.000000
- Shares after
- 290,500
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 290,500
- Exercise price
- $1.13
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
Footnote F2
Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
Footnote F3
Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
Footnote F4
Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
Footnote F5
Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
Footnote F6
The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.